Ovarian stimulation for IVF is a crucial step in fertility treatment, designed to encourage the ovaries to produce multiple mature eggs for retrieval. This process significantly increases the chances of successful In vitro fertilisation (IVF) by providing more usable embryos. Understanding the science behind it, from choosing the right dose to monitoring progress, is key for students and patients alike.
Ovarian Stimulation for IVF: An Overview
The primary goal of ovarian stimulation for IVF is to increase the number of oocytes retrieved, leading to more usable embryos and ultimately a higher cumulative live birth rate. While more oocytes are generally better, there are important tradeoffs to consider, such as the risk of Ovarian Hyperstimulation Syndrome (OHSS), treatment cost, and patient burden.
The Physiology Behind Ovarian Stimulation
To effectively stimulate the ovaries, we must understand and override natural physiological processes. Three core concepts are essential:
- The FSH Window: In a natural cycle, the Follicle-Stimulating Hormone (FSH) level drops, causing most follicles to undergo atresia. Stimulation aims to keep this FSH window open longer, allowing more follicles to grow.
- The FSH Threshold: Each follicle has a unique sensitivity to FSH. Lower-threshold follicles are recruited first. Ovarian stimulation provides higher and more sustained FSH levels, rescuing more follicles from atresia.
- Atresia: This is the natural default fate for most follicles. Stimulation is essentially a rescue mission, preventing follicles from degenerating.
Additionally, Luteinizing Hormone (LH) plays three vital roles: providing androgen substrate for estrogen production, inducing LH receptors on granulosa cells of large follicles, and triggering maturation and ovulation (which we replace with a trigger drug during IVF).
What Stimulation Must Achieve
To move from a natural cycle to a stimulated one, IVF protocols must:
- Widen the FSH window: This keeps more follicles growing above their threshold.
- Prevent a premature endogenous LH surge: An unplanned surge would lead to premature ovulation and a lost cycle.
- Replace the surge at a chosen time: A trigger drug dictates when eggs mature, rather than the patient's pituitary.
- Support the iatrogenic luteal phase: The stimulation process can disrupt the natural luteal phase, making support mandatory, especially for fresh embryo transfers.
Flashcards
Tap to flip · Swipe to navigate
Building Blocks of an Ovarian Stimulation Protocol
An IVF stimulation protocol is a carefully constructed plan involving several components.
FSH Products: The Engine of Stimulation
FSH is the main hormone used to stimulate follicle growth. Options include:
- Recombinant FSH (rFSH): Such as Gonal-F, Puregon, Rekovelle, and Elonva (long-acting).
- Urinary FSH: Such as Fostimon.
- Human Menopausal Gonadotropin (hMG): Menopur, which contains both FSH and LH activity (mostly hCG).
- Biosimilars: Cost-effective alternatives to originator rFSH products like Bemfola and Ovaleap, proven clinically equivalent.
For embryologists, the dose and timing of FSH are far more critical than the specific product chosen. The starting FSH dose, the duration of the FSH window, and the cohort distribution at trigger are key diagnostic numbers.
The Role of LH Activity
While most patients have sufficient endogenous LH, exogenous LH activity (from products like Menopur, Luveris, or Pergoveris) is clearly indicated for patients with hypogonadotrophic hypogonadism. Its benefit in other groups, like older women or poor responders, remains contested with weaker evidence.
Surge Suppression: Preventing Premature Ovulation
Preventing an early LH surge is critical. Common strategies include:
- Long Agonist Protocol: The original method, using a GnRH agonist to downregulate the pituitary, offering predictable response and tight scheduling. However, it involves more injections, higher OHSS risk (as agonist trigger can't be used), and a menopausal flare during downregulation. It's now used selectively.
- Antagonist Protocol: The current default. GnRH antagonist is added mid-stimulation (around day 5-6 or when a lead follicle reaches 14mm) to block the LH surge. Its advantages include shorter protocol, fewer injections, lower OHSS risk (as agonist trigger is possible), and equivalent outcomes to long agonist. A